Apotex recalls nearly 50,000 bottles of torsemide tablets

Canada's Apotex is recalling nearly 50,000 bottles of 5 mg and 20 mg torsemide tablets.

Canadian generic producer Apotex has a new recall to deal with, this time for nearly 50,000 bottles of a diuretic.

According to the most recent FDA Enforcement Report, the company is recalling one lot of 5 mg torsemide tablets, consisting of 13,179 bottles or 1,317,900 pills. It is also recalling three lots of 20 mg tablets, consisting of 35,819 bottles or 358,190,000 pills.

The report said the tablets were manufactured at Apotex’s plant in Toronto. They are being recalled for cGMP deviations, but the report gave specifics on what those deviations are. The recall began Dec. 14 and was just posted by the FDA.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Apotex had another much larger recall in July when it retrieved about 1.5 million bottles of duloxetine delayed-release capsules, a generic of Cymbalta.

Apotex, perhaps the largest generic drug producer in North America, has a long history of FDA issues. The agency issued a warning letter to Apotex in 2015 for two plants in Bangalore, India. The FDA said the facilities were discovered manipulating testing data, a practice it said had gone on for years.


Suggested Articles

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.  

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.